STOCK TITAN

ANTHERA PHARMS INC NEW - $ANTH STOCK NEWS

Welcome to our dedicated page for ANTHERA PHARMS NEW news (Ticker: $ANTH), a resource for investors and traders seeking the latest updates and insights on ANTHERA PHARMS NEW stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANTHERA PHARMS NEW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANTHERA PHARMS NEW's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ANTHERA PHARMS INC NEW

NYSE:ANTH

ANTH Rankings

ANTH Stock Data

6.18k
26.13M
7.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Hayward

About ANTH

anthera pharmaceuticals, inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. anthera has two product candidates, sollpura, in phase 3 development for exocrine pancreatic insufficiency due to cystic fibrosis and blisibimod, in phase 2 development for iga nephropathy. nasdaq: anth